Additionally, systematically inhibiting ERRα may induce nonalcoholic steatohepatitis (NASH), behavioral disturbances, or other adverse events, hindering its clinical application26,27. Here, ESRRA is linked to metabolic dysfunction-associated steatohepatitis.